Bayer Menopause Drug Meets Key Goal in Late-Stage Trial
By Adria Calatayud
Bayer said investigational drug elinzanetant met its primary goal by reducing symptoms linked to menopause in a late-stage clinical trial, paving the way for submissions to health authorities for approval.
The German pharmaceutical-and-agricultural group said Tuesday that elinzanetant showed a statistically significant reduction in the frequency of moderate to severe vasomotor symptoms, also known as hot flashes, compared to placebo. The long-term safety profile observed over 52 weeks in the phase 3 trial is overall consistent with previously conducted studies, the company said.
The study comes after Bayer reported positive results for two late-stage studies of the same drug.
Bayer said it will submit data from the studies to health authorities for approval of elinzanetant for the treatment of moderate to severe vasomotor symptoms associated with menopause.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
March 19, 2024 03:48 ET (07:48 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy